Stéphane Bancel, Moderna CEO (Nancy Lane/The Boston Herald via AP Images, Pool)
July 15, 2021 10:34 AM EDT
Bioregnum

With Mod­er­na shares fly­ing at a pan­dem­ic high, the mar­ket cap has now pierced the $100B mark, leapfrog­ging Glax­o­SmithK­line

Back just be­fore the pan­dem­ic hit the world in ear­ly 2020, Mod­er­na’s shares were trad­ing right around $20 a share. To­day, it’s above $250 a …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times